{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:59:01Z","timestamp":1790837941906,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies on herpes zoster (HZ) incidence in solid organ transplant (SOT) recipients report widely varying numbers. We investigated HZ incidence, severity, and risk factors in recipients of four different SOTs, with a follow-up time of 6\u201314 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Records of 1,033 transplant recipients after first heart (HTx: n = 211), lung (LuTx: n = 121), liver (LiTx: n = 258) and kidney (KTx: n = 443) transplantation between 2000 and 2014 were analyzed for VZV-PCR, clinical signs of HZ, and complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HZ was diagnosed in 108 of 1,033 patients (10.5%): 36 HTx, 17 LuTx, 15 LiTx, and 40 KTx recipients. Overall HZ incidence rate after HTx (30.7 cases\/1,000 person\u2013years (PY)), LuTx (38.8 cases\/1,000 PY), LiTx (22.7 cases\/1,000 PY) and KTx (14.5 cases\/1,000 PY) was significantly higher than in the general 50\u201370 year population. Multivariable analysis demonstrated age \u226550 years at transplantation (p = 0.038, RR 1.536), type of organ transplant (overall p = 0.002; LuTx p = 0.393; RR 1.314; LiTx p = 0.011, RR 0.444; KTx p = 0.034, RR 0.575), CMV prophylaxis (p = 0.043, RR 0.631) and type of anti-rejection therapy (overall p = 0.020; methylprednisolone p = 0.008, RR 0.475; r-ATG p\u00a0=\u00a00.64, RR1.194) as significant risk factors. Complications occurred in 33 of 108 (31%) patients (39% of HTx, 47% of LuTx, 20% of LiTx, 20% of KTx): post-herpetic neuralgia, disseminated disease, and cranial nerve involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HZ incidence and severity in SOT recipients are most pronounced after heart and lung transplantation, in older patients, and when CMV prophylaxis is lacking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2021.645718","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T02:26:10Z","timestamp":1616034370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Herpes Zoster in Solid Organ Transplantation: Incidence and Risk Factors"],"prefix":"10.3389","volume":"12","author":[{"given":"Marcia M. L.","family":"Kho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Roest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique M.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier A. S.","family":"Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek A.","family":"van der Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke I.","family":"Roodnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"van Besouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0738-081X(89)90027-8","article-title":"Herpes zoster","volume":"7","author":"Blumberg","year":"1989","journal-title":"Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.055","article-title":"Varicella in Europe-A review of the epidemiology and experience with vaccination","volume":"33","author":"Helmuth","year":"2015","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12879-016-1369-6","article-title":"Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40520-018-0956-3","article-title":"Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies","volume":"30","author":"Zorzoli","year":"2018","journal-title":"Aging Clin Exp Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.06.010","article-title":"Incidence of herpes zoster amongst adults varies by severity of immunosuppression","volume":"75","author":"Schroder","year":"2017","journal-title":"J Infect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1432-2277.1995.tb01708.x","article-title":"Herpes zoster-associated idiopathic thrombocytopenic purpura in a liver transplant recipient: a case report and overview","volume":"8","author":"Singh","year":"1995","journal-title":"Transpl Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12106","article-title":"Ramsay Hunt syndrome with an unusual clinical presentation in a liver transplant recipient: a case report and literature review","volume":"26","author":"Feng","year":"2013","journal-title":"Transpl Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014","volume":"20","author":"Mu\u00f1oz-Quiles","year":"2020","journal-title":"BMC Infect Diseases"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12107","article-title":"Varicella zoster virus in solid organ transplantation","author":"Pergam","year":"2013","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.11.1581","article-title":"Postherpetic neuralgia: epidemiology, pathophysiology and management","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00289.x","article-title":"Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis","volume":"10","author":"Arness","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-3062.2010.00547.x","article-title":"Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients","volume":"13","author":"Pergam","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00287.x","article-title":"Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era","volume":"4","author":"Gourishankar","year":"2004","journal-title":"Am J Transpl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/tid.12149","article-title":"Incidence and risk factors for herpes zoster following heart transplantation","volume":"16","author":"Koo","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.09.028","article-title":"Incidence and clinical characteristics of herpes zoster after lung transplantation","volume":"27","author":"Manuel","year":"2008","journal-title":"J Heart Lung Transpl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12425","article-title":"Incidence and risk factors for herpes zoster in patients undergoing liver transplantation","volume":"17","author":"Hamaguchi","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12091","article-title":"Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation","volume":"15","author":"Ko","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e13519","DOI":"10.1111\/tid.13519","article-title":"Epidemiology and risk factors for varicella zoster virus reactivation in heart transplant recipients","volume":"21","author":"La Hoz","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.08.060","article-title":"Varicella infection in adult renal allograft recipients: experience at one center","volume":"38","author":"Rodriguez-Moreno","year":"2006","journal-title":"Transplant Proc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13076","article-title":"Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study","volume":"31","author":"Fernandez-Ruiz","year":"2018","journal-title":"Transpl Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12879-015-1038-1","article-title":"Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis","volume":"15","author":"Pavlopoulou","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14192","article-title":"Preventive Strategies Against Cytomegalovirus and Incidence of alpha-Herpesvirus Infections in Solid Organ Transplant Recipients: A Nationwide Cohort Study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am J Transpl"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1403062","article-title":"Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.029","article-title":"Varicella zoster virus infection occurs at a relatively young age in The Netherlands","volume":"31","author":"van Lier","year":"2013","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.043","article-title":"Humoral and cellular response after varicella vaccination in VZV IgG seronegative kidney transplant candidates","volume":"35","author":"Kho","year":"2017","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jneuroim.2018.05.005","article-title":"Long-term outcomes of varicella zoster virus infection-related myelitis in 10 immunocompetent patients","volume":"321","author":"Wang","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199403313301304","article-title":"A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.110","article-title":"Premature aging of circulating T cells in patients with end-stage renal disease","volume":"80","author":"Betjes","year":"2011","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.03.018","article-title":"Risk of herpes zoster in CKD: a matched-cohort study based on administrative data","volume":"60","author":"Wu","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2019","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv432","article-title":"Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease","volume":"31","author":"Langan","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1111\/tid.12874","article-title":"A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation","volume":"20","author":"Miller","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.645718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T02:26:12Z","timestamp":1616034372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.645718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2021.645718"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.645718","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"article-number":"645718"}}